New vaccine aims to protect infants from deadly diarrhea
NCT ID NCT04056117
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new vaccine called Shigella4V, designed to protect against shigellosis, a severe diarrheal disease. Researchers are giving the vaccine to healthy adults, children, and 9-month-old infants to check its safety and whether it triggers a strong immune response. Different doses are being tested to find the best one for infants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Shigella4V vaccine
- What this could lead to
- If successful, this vaccine could protect infants and children from severe diarrheal disease caused by Shigella bacteria, reducing illness and death in regions where it is common.
- What could go wrong
- This is an early-phase trial, so the vaccine may not prove effective or may cause side effects. Results in adults may not predict how well it works in infants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHIGELLOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
KEMRI-Centre Geographic Medical Research-COAST (KEMRI-CGMRC)
Kilifi, 230-80108, Kenya
-
Kenya Medical Research Institute (KEMRI)/ United States Army Medical Research Directorate- Kenya (USAMRD-K)
Kericho, 1357-20200, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.